Bone Marrow Transplant (BMT)

Introduction

A bone marrow transplant (BMT) is one of the most intensive treatments in modern medicine, and also one of the most hopeful. For people with serious blood cancers, bone marrow failure, inherited blood disorders, or severe immune deficiencies, a transplant can offer the possibility of long-term disease control or cure when standard treatments are not enough.

If you or a family member has been referred for a bone marrow transplant, you are likely facing a lot of new information at once. The process is long. It unfolds in stages over many months, from the first evaluation through donor matching, conditioning treatment, the transplant itself, hospital recovery, and the slow rebuilding of the immune system. Each stage has its own questions, its own risks, and its own milestones.

This guide walks through the full arc of bone marrow transplant in plain language. It explains what bone marrow does, why a transplant may be needed, the different types of transplant, how donors are matched, what happens during the procedure, what recovery looks like, and how life unfolds afterwards. The goal is to help you understand the medical landscape so that you can have clearer conversations with your transplant team and feel more prepared for each step.

What Is a Bone Marrow Transplant?

A bone marrow transplant, also known as a hematopoietic stem cell transplant (HSCT), is a treatment that replaces unhealthy or destroyed bone marrow with healthy blood-forming stem cells. Although it is called a “transplant,” it does not involve surgery in the traditional sense. The stem cells are given through a drip into a vein, similar to a blood transfusion. From there, the cells travel through the bloodstream to the bones, where they settle and begin producing new, healthy blood cells.

Understanding bone marrow

Bone marrow is the soft, spongy tissue found inside many of your bones, including the pelvis, breastbone, ribs, spine, and the long bones of the arms and legs. It is the body’s blood factory. Inside the marrow, blood-forming (hematopoietic) stem cells continuously produce three main types of blood cells:

• Red blood cells, which carry oxygen from the lungs to the rest of the body
• White blood cells, which fight infection and support immunity
• Platelets, which help blood clot and stop bleeding

When the marrow becomes diseased — for example, because of leukaemia, an inherited disorder, or damage from treatment — it can no longer produce enough healthy blood cells. The result can be severe anaemia, dangerous infections, bleeding problems, and life-threatening complications.

What a transplant does

A bone marrow transplant aims to restart healthy blood and immune cell production. Depending on the situation, it may also serve another purpose: in some blood cancers, donor immune cells delivered through the transplant can recognise and attack any remaining cancer cells. This is called the graft-versus-tumour effect, and it is one of the reasons transplant can lead to long-term remission in conditions that would otherwise be very difficult to control.

Who Is a Bone Marrow Transplant For?

Bone marrow transplant is considered when the bone marrow is no longer working properly, when a disease has a high risk of returning after standard treatment, or when very high doses of chemotherapy are needed and a transplant is the only way to rescue the blood and immune system afterwards.

Conditions commonly treated with BMT

Transplant teams may consider BMT for a range of conditions, including:

Blood cancers:

• Acute myeloid leukaemia (AML)
• Acute lymphoblastic leukaemia (ALL)
• Chronic myeloid leukaemia (CML), in selected cases
• Hodgkin lymphoma
• Non-Hodgkin lymphoma
• Multiple myeloma

Bone marrow failure and pre-leukaemic conditions:

• Aplastic anaemia
• Myelodysplastic syndromes (MDS)
• Other bone marrow failure syndromes

Inherited blood disorders:

• Thalassemia
• Sickle cell disease
• Fanconi anaemia

Immune deficiency disorders:

• Severe combined immunodeficiency (SCID)
• Other inherited primary immunodeficiencies

Certain inherited metabolic disorders, particularly in children, where replacing the marrow can correct a missing enzyme produced by blood cells.

How candidacy is decided

Whether a transplant is appropriate depends on many factors. Transplant teams typically consider:

• The exact diagnosis and how aggressive the disease is
• How the disease has responded to earlier treatments
• Age and overall fitness
• Heart, lung, liver, and kidney function
• Presence of infections
• Availability of a suitable donor (for allogeneic transplant)
• The patient’s and family’s ability to manage the long recovery, including time away from work or school

The decision is rarely simple. Major haematology and transplant societies recommend that candidacy be evaluated by a multidisciplinary transplant team, which weighs the potential benefits against the risks for each individual.

Types of Bone Marrow Transplant

Autologous bone marrow transplant

In an autologous transplant, the patient’s own stem cells are used. The cells are collected before high-dose chemotherapy, frozen, and stored. After chemotherapy has destroyed the diseased cells (and, unavoidably, much of the healthy bone marrow), the stored stem cells are thawed and given back through a drip to rebuild the marrow.

Autologous transplant is most often used for:

• Multiple myeloma
• Hodgkin lymphoma, particularly when the disease has returned after first-line treatment
• Certain non-Hodgkin lymphomas
• Some solid tumours in selected situations

What it offers:

• No donor is required
• No risk of graft-versus-host disease (because the cells are the patient’s own)
• Generally faster immune recovery than allogeneic transplant

Its limitations:

• It does not provide a new, healthy immune system, so it does not produce a graft-versus-tumour effect
• There is a small risk that a few disease cells may be present in the stored sample
• It is not suitable for conditions where the bone marrow itself is the source of the disease, such as most leukaemias

Allogeneic bone marrow transplant

In an allogeneic transplant, healthy stem cells come from another person — the donor. The donor’s tissue type must closely match the patient’s to reduce the risk of immune complications.

Donors may be:

• A matched sibling (brother or sister)
• A matched unrelated donor identified through international donor registries
• A haploidentical (half-matched) family member, such as a parent or child
• An umbilical cord blood unit stored in a cord blood bank

Allogeneic transplant is commonly considered for:

• Acute and chronic leukaemias
• Severe aplastic anaemia
• Myelodysplastic syndromes
• Inherited blood disorders such as thalassemia and sickle cell disease
• Some inherited immune deficiencies

What it offers:

• A completely new blood and immune system, free of the original disease
• A graft-versus-tumour effect, where donor immune cells can attack remaining cancer cells
• The possibility of long-term cure in conditions where this is otherwise hard to achieve

Its limitations:

• Risk of graft-versus-host disease (GVHD), where donor cells attack the patient’s tissues
• Longer immune recovery, sometimes a year or more
• Higher risk of serious infections during recovery
• Need for long-term medications to suppress the immune system

Reduced-intensity (“mini”) transplants

Traditional allogeneic transplants use very high doses of chemotherapy and sometimes radiation to destroy the diseased marrow before the donor cells are given. For older patients or those with other medical conditions, doctors may instead use a reduced-intensity conditioning (RIC) regimen. This uses lower doses of chemotherapy and relies more on the donor immune cells to control the disease. It can make transplant possible for people who would not safely tolerate full-intensity conditioning, although the risk of disease returning may be higher.

Sources of Stem Cells

Stem cells for transplant can be collected from three sources. The choice depends on the type of transplant, the donor, and the patient’s situation.

Peripheral blood stem cells

This is the most common source today. The donor receives daily injections of a medication (a growth factor) for several days that prompts the bone marrow to release stem cells into the bloodstream. The cells are then collected through a process called apheresis, in which blood is drawn from one arm, passed through a machine that separates out the stem cells, and the rest of the blood is returned through the other arm. The process takes a few hours and is usually done as an outpatient procedure.

Bone marrow harvest

Stem cells can also be collected directly from the bone marrow itself, usually from the back of the pelvic bone. The donor is given general or regional anaesthesia, and the marrow is drawn out through a needle. The donor may have some soreness in the lower back for a few days. This source is still used in many situations, particularly for some paediatric transplants.

Umbilical cord blood

Blood from the umbilical cord and placenta, collected at the time of a baby’s birth, is rich in stem cells. It can be stored in cord blood banks and used for transplant later. Cord blood does not need to be as closely matched as adult donor cells, which makes it useful when a fully matched donor cannot be found. The trade-off is that the number of stem cells in a single cord blood unit is smaller, which can mean slower engraftment.

Donor Matching and HLA Typing

For an allogeneic transplant, donor matching is one of the most important steps. The matching process is based on human leukocyte antigens (HLA), proteins on the surface of cells that the immune system uses to tell “self” from “non-self.” The closer the donor’s HLA type matches the patient’s, the lower the risk of graft rejection and serious GVHD.

How matching works

HLA typing is done with a blood test or a swab from the inside of the cheek. Doctors typically look at several specific HLA markers. A fully matched sibling shares all the major markers, and this is usually the preferred option when available. However, only about one in four siblings will be a full match.

When no sibling match is available, the transplant team searches international unrelated donor registries. Finding a match this way depends on ethnicity and genetic background — some populations are well represented in donor registries, while others are not, which can make finding a match harder.

Haploidentical and alternative donors

Advances in transplant techniques have made it possible to use half-matched (haploidentical) family donors, such as a parent or child, with good outcomes. This is especially helpful when no fully matched donor can be found and is becoming more widely available. Cord blood is another alternative when matching is difficult.

The Bone Marrow Transplant Process: Step by Step

Step 1: Pre-transplant evaluation

Before a transplant can proceed, the team performs a thorough evaluation to confirm the diagnosis, assess overall health, and identify any issues that may need attention. Typical tests include:

• Complete blood counts and bone marrow biopsy
• Cytogenetic and molecular tests on the bone marrow
• Imaging such as CT or PET scans
• Heart tests (ECG, echocardiogram)
• Lung function tests
• Liver and kidney function tests
• Screening for infections such as hepatitis, HIV, and CMV
• Dental check-up to address any sources of infection
• Nutritional assessment
• Psychological evaluation and counselling

For allogeneic transplant, donor selection and HLA typing happen during this phase. The team also discusses fertility preservation options, since high-dose chemotherapy can affect fertility.

Step 2: Stem cell collection

For autologous transplant, the patient’s own stem cells are collected (most often from the peripheral blood) and stored. For allogeneic transplant, the donor undergoes collection — usually peripheral blood apheresis, sometimes bone marrow harvest. If cord blood is being used, the unit is shipped from a cord blood bank.

Step 3: Central line placement

A central venous catheter (often called a central line or Hickman line) is placed into a large vein, usually in the chest. This stays in place for weeks or months and is used to give chemotherapy, fluids, medications, blood products, the stem cells themselves, and to draw blood samples without repeated needle sticks.

Step 4: Conditioning therapy

Conditioning is the high-dose treatment given just before the transplant. It typically involves several days of chemotherapy, sometimes combined with total body radiation. Conditioning has three goals:

• To destroy any remaining diseased cells
• To make space in the bone marrow for the new cells
• For allogeneic transplant, to suppress the immune system so it does not reject the donor cells

Conditioning is intensive and often causes side effects such as nausea, mouth sores, fatigue, hair loss, and a drop in blood counts. Patients are usually admitted to a specialised transplant unit during this time.

Step 5: The transplant (stem cell infusion)

The transplant itself is anticlimactic compared to the build-up. The stem cells are given through the central line as a slow infusion, much like a blood transfusion. It usually takes between one and several hours. Most patients feel relatively little during the infusion, although some experience a strange taste or smell, mild fever, or nausea from the preservatives used to freeze the cells.

The day of the infusion is often called “day zero,” and the days that follow are counted from there (day +1, day +2, and so on).

Step 6: Engraftment

Engraftment is the point at which the transplanted stem cells settle into the bone marrow and start producing new blood cells. It typically happens:

• Around 10 to 20 days after an autologous transplant
• Around 2 to 4 weeks after an allogeneic transplant
• Sometimes longer with cord blood, where engraftment can be slower

Until engraftment occurs, blood counts are very low. This period is when the risk of infection and bleeding is highest, and patients are closely monitored. Frequent blood transfusions and platelet transfusions may be needed. The team watches blood counts daily and looks for the first signs of new cells appearing — an encouraging milestone.

Step 7: Early recovery in hospital

Most patients remain in hospital for several weeks during and after the transplant. Length of stay depends on the type of transplant, how quickly engraftment occurs, and whether complications arise. Typical hospital stays are around 2 to 4 weeks for autologous transplant and 4 to 6 weeks or more for allogeneic transplant.

During this time, care focuses on:

• Protective isolation to reduce infection exposure
• Intravenous fluids, nutrition, and medications
• Antibiotics, antivirals, and antifungal medicines
• Blood and platelet transfusions as needed
• Pain control and management of mouth sores
• Daily blood tests and clinical monitoring

Step 8: Discharge and outpatient recovery

Once blood counts are recovering, complications are under control, and the patient is medically stable, discharge becomes possible. For the first weeks to months after discharge, frequent outpatient visits are needed — sometimes several times a week initially — for blood tests, examinations, and medication adjustments. Patients are usually asked to stay near the transplant centre during this period in case urgent care is needed.

Recovery and Healing

The first month

This is the most fragile time. Blood counts are still low or only just recovering. The risk of infection is at its highest. Most patients experience significant fatigue, weakness, poor appetite, mouth sores, and changes in taste. Emotional ups and downs are very common.

One to three months

Blood counts continue to improve. Energy slowly returns, although fatigue often remains significant. Frequent clinic visits continue. Medications to prevent infection and, in allogeneic transplant, to suppress GVHD are usually still being adjusted. Eating and drinking become easier as mouth sores heal.

Three to six months

Many patients begin to feel meaningfully stronger. Hair regrows, often with a different texture or colour at first. Light daily activities become more manageable. Hospital and clinic visits become less frequent. For autologous transplant patients, this is often when a more normal routine starts to feel possible.

Six to twelve months

The immune system continues to rebuild. Doctors typically restart childhood vaccinations during this period because the new immune system has lost the protection of earlier vaccinations. Most patients have regained much of their strength, though full recovery often takes longer than expected. Long-term follow-up visits become less frequent but continue.

Beyond one year

For allogeneic transplant patients, immune recovery may continue for two years or more. Long-term medications may still be needed if chronic GVHD is present. Annual follow-up to check for late effects continues for many years, sometimes for life.

Risks and Complications

Bone marrow transplant carries significant risks. Being aware of them helps you and your family recognise problems early and ask the right questions of your team.

Infections

Because the immune system is severely weakened during conditioning and the early weeks after transplant, infections are the most common serious complication. Bacterial, viral, and fungal infections can all occur. Preventive antibiotics, antivirals, and antifungals are routinely given, and any fever is taken seriously and investigated promptly.

Bleeding

GVHD is a complication unique to allogeneic transplant. It occurs when the donor’s immune cells recognise the patient’s tissues as foreign and attack them. GVHD can be:

• Acute GVHD, usually in the first months after transplant. It most often affects the skin (rash), the gut (diarrhoea, nausea), and the liver (jaundice, abnormal liver tests).
• Chronic GVHD, which may develop later and can affect skin, eyes, mouth, joints, lungs, and other organs over a long period.

GVHD is treated with medications that suppress the immune system, such as steroids and other immunosuppressants. Some donor immune activity against the disease (graft-versus-tumour effect) is actually beneficial, so the goal is to keep GVHD controlled without losing this protective effect.

Graft failure

In a small number of cases, the transplanted stem cells do not engraft properly, or the body rejects them. This is more common with reduced-intensity conditioning, mismatched donors, or cord blood transplants. If graft failure occurs, further treatment options — including a second transplant — may be considered.

Organ damage

High-dose chemotherapy and radiation can affect the heart, lungs, liver, and kidneys. Some effects appear early; others may develop years later.

Fertility and hormonal effects

Conditioning treatment can cause infertility in both men and women, and affect ovarian or testicular hormone production. If preserving fertility is important, this is usually discussed before transplant so options such as sperm banking or egg/embryo freezing can be considered.

Secondary cancers

Years after transplant, there is a small increased risk of developing other cancers. Long-term follow-up includes screening for these late effects.

Relapse of the original disease

For patients transplanted for cancer, there is always a risk that the disease may return. The likelihood depends on the type of disease, how well it had responded to earlier treatment, and the type of transplant. If relapse occurs, further treatments may still be possible.

Living During and After Transplant

Protective isolation and infection prevention

During the first months after transplant, daily life involves taking active steps to avoid infection. Common precautions include:

• Strict hand hygiene for the patient and everyone in the household
• Wearing a mask in public spaces and around people with colds or coughs
• Avoiding crowded indoor settings
• Avoiding people who are ill or recently vaccinated with live vaccines
• Avoiding contact with soil, fresh flowers, or potted plants for a period of time
• Following safe food practices (no undercooked meat, eggs, or unpasteurised dairy; well-washed fruits and vegetables)
• Following the medication schedule exactly, including preventive antibiotics, antivirals, and antifungals

Nutrition

Eating well is one of the most important parts of recovery. Appetite is often poor at first, and taste changes are common. Small, frequent meals usually work better than large ones. Adequate protein, calories, and fluid help the body heal. A neutropenic or low-microbial diet may be recommended for a defined period to reduce infection risk from food. A dietitian linked to the transplant team can help tailor advice.

Physical activity

Gentle physical activity helps with fatigue, mood, and recovery of strength. Walking, gentle stretching, and light exercise are usually encouraged as early as possible and gradually increased. A physiotherapist may help design a programme that fits each stage of recovery.

Emotional and mental health

The emotional toll of a bone marrow transplant is often as challenging as the physical toll. Common feelings include:

• Anxiety about complications and relapse
• Frustration at slow recovery
• Loneliness during isolation
• Depression, especially in the months after discharge
• Survivor’s guilt, in some cases
• Stress on family relationships and caregivers

Psychological support, peer support groups, and counselling can be valuable through all phases of transplant. Caregivers also need support — the role of caring for someone through transplant is demanding and exhausting.

Returning to work, school, and social life

How quickly people return to work, school, or social activities varies widely. Some autologous transplant patients return to part-time work within a few months. Many allogeneic transplant patients take a year or more before resuming full activities, and some may need permanent adjustments. Decisions about return to work, school, travel, and other activities are usually made gradually, in consultation with the transplant team.

Bone Marrow Transplant in Children

Children undergo bone marrow transplant for many of the same conditions as adults — leukaemias, lymphomas, aplastic anaemia — and for some that are mostly seen in childhood, such as severe combined immunodeficiency (SCID), thalassemia, sickle cell disease, and certain inherited metabolic disorders. In some of these conditions, transplant in childhood can be curative.

Differences in paediatric transplant

Paediatric transplant teams are organised around the specific needs of children and families. Important differences include:

• Donor sources: Sibling donors, including very young siblings with parental consent, are commonly used when available. Cord blood is used more often in children than in adults because smaller body size matches the cell numbers available in a cord unit.
• Conditioning regimens: Paediatric protocols are adjusted for body size, age, and the type of disease. The long-term effects of chemotherapy and radiation on growing bodies are a particular concern.
• Growth and development: Conditioning treatments can affect growth, puberty, and hormone production. Endocrine specialists are usually involved in long-term follow-up.
• Fertility: Discussions about future fertility happen with the child’s parents and, where age-appropriate, the child. Fertility preservation options exist but are limited in very young children.
• School and learning: Long hospital stays and recovery can affect schooling. Many transplant units have teachers or play specialists, and schools usually work with the family on a phased return.
• Family-centred care: Parents are closely involved in care decisions and day-to-day support. Siblings may also need attention and support, especially if one is a donor.

Long-term follow-up in children

Children who have had a transplant need follow-up for many years — often into adult life. This includes monitoring for late effects on growth, hormones, fertility, heart and lung function, and the small long-term risk of secondary cancers. Many transplant centres have dedicated long-term follow-up clinics for transplant survivors.

Long-Term Outlook and Follow-up

What success means

For some conditions, a successful bone marrow transplant can mean a cure or very long-term disease control. For others, transplant can lead to long remission with the possibility of further treatment if the disease returns. Outcomes vary substantially depending on:

• The specific disease and how advanced it was at transplant
• How the disease responded to earlier treatment
• Type of transplant (autologous vs allogeneic) and donor match
• Age and overall health
• Whether and how complications such as GVHD and infections develop

Because outcomes depend on so many individual factors, the most useful estimates come from your own transplant team, who can frame the likely range for your specific situation. Major haematology societies advise against relying on generic survival figures for personal decision-making.

Long-term follow-up visits

Long-term follow-up typically includes:

• Blood tests to monitor blood counts, organ function, and (in cancer) signs of relapse
• Bone marrow tests if needed
• Heart and lung assessments
• Bone density tests, as bone health can be affected
• Endocrine and fertility evaluations
• Skin examinations and eye check-ups (particularly important in chronic GVHD)
• Screening for secondary cancers
• Re-vaccination according to a planned schedule, starting around 6 to 12 months after transplant

Life after transplant

Many transplant survivors return to active, meaningful lives — working, studying, raising families, travelling, and engaging in the things that matter to them. Some live with ongoing effects of treatment, such as chronic GVHD, fatigue, or hormonal changes, and adapt their lives accordingly. The experience often leaves a mark, but for many, it is one chapter in a longer life rather than the defining one.

Frequently Asked Questions

Is a bone marrow transplant the same as a stem cell transplant?

Yes — the two terms are used interchangeably. The more technical name is hematopoietic stem cell transplant (HSCT). “Bone marrow transplant” is the more familiar term and refers to the same treatment, whether the stem cells come from bone marrow, peripheral blood, or cord blood.

Is the procedure painful?

The stem cell infusion itself is usually not painful and feels similar to receiving a blood transfusion. The conditioning treatment beforehand and the recovery period afterwards can cause discomfort — mouth sores, nausea, fatigue, and infection symptoms are common. The transplant team uses medications to manage pain and other symptoms.

How long will I be in hospital?

Hospital stays typically range from about 2 to 4 weeks for autologous transplant and 4 to 6 weeks or more for allogeneic transplant. Stays can be longer if complications develop. After discharge, frequent outpatient visits continue for weeks to months.

Is a donor always needed?

No. In an autologous transplant, your own stem cells are used and no donor is required. Donors are needed for allogeneic transplant. Even then, options have widened in recent years: matched siblings, matched unrelated donors, half-matched family donors, and cord blood units can all be considered.

What happens if a fully matched donor cannot be found?

Modern transplant techniques have made it possible to safely use half-matched (haploidentical) family donors and cord blood units when a full match is not available. The transplant team will discuss the best option based on the disease, urgency, and family situation.

Can a bone marrow transplant cure my disease?

For some conditions — certain leukaemias, severe aplastic anaemia, thalassemia, sickle cell disease, some immune deficiencies, and others — transplant offers the possibility of cure. For others, it can provide long-term disease control or remission. Whether cure is realistic in your case depends on the specific diagnosis and many other factors; your transplant team is the right source for that conversation.

Will the donor look or feel different from me afterwards?

No. After an allogeneic transplant, your blood cells will share the donor’s DNA, but your appearance, personality, and identity remain your own. Blood type can change to that of the donor over time, which can be a surprise but is harmless.

Can I have children after a bone marrow transplant?

Conditioning chemotherapy and radiation often affect fertility, sometimes permanently. This varies with the regimen used, age at transplant, and individual factors. Fertility preservation options such as sperm, egg, or embryo freezing are usually discussed before transplant. Successful pregnancies after transplant do happen, though they may need specialist support.

When can I get back to normal activities?

The pace of return to normal activities varies widely. Many autologous transplant patients resume routine activities within several months. Allogeneic transplant patients often need a year or more for fuller recovery. Decisions about returning to work, school, and travel are made step by step, guided by the transplant team.

Do I need to keep taking medications for life?

After autologous transplant, long-term medications are usually not needed once recovery is complete. After allogeneic transplant, immune-suppressing medications are typically needed for months and sometimes longer, particularly if GVHD develops. Some patients eventually come off most medications; others may need ongoing treatment.

How will I know if the transplant has worked?

The first sign is engraftment — the recovery of blood counts in the weeks after transplant. After that, your team will use blood tests, bone marrow tests, and imaging or other studies (depending on the original disease) to track how well the transplant is controlling the disease. Follow-up continues for years.

Conclusion

A bone marrow transplant is a long, demanding, and deeply personal journey. It can also be transformative — offering the chance of cure or long-term control for diseases that are otherwise very hard to treat. The process unfolds in clear stages, from evaluation and donor matching through conditioning, infusion, engraftment, hospital recovery, and the slow rebuilding of strength and immunity over many months.

Understanding what to expect at each stage — the types of transplant, the role of the donor, the risks of GVHD and infection, the rhythm of recovery, and the long-term follow-up — can make the experience feel less unknown. The most important conversations are the ones with your transplant team, who can apply this general picture to your specific situation, weigh the options together with you and your family, and walk alongside you through each step.